Multiple sclerosis (MS) is a relentless disease, and one with a rising prevalence. The National Institutes of Health estimates that some 200 cases are diagnosed every week in the U.S. alone. The advent of oral therapies is a hopeful sign in the effort to slow progression of the disease. The approval of three MS drugs so far in 2013 – followed by a pipeline brimming with hundreds of compounds – speaks to the resources the biopharma industry is aiming at the disease. (See BioWorld Insight, Nov. 4, 2013.)